From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access

References

• Sachs JD, Abdool Karim S, Aknin L. Lancet COVID-19 Commissioners, Task Force Chairs, and Commission Secretariat. Lancet COVID-19 commission statement on the occasion of the 75th session of the UN General Assembly. Lancet. 2020 Oct 10;396(10257):1102–1124.
   PubMed Web of Science ®Google Scholar
• Sachs JD, Abdool Karim S, Aknin L. Commissioners of the Lancet COVID-19 Commission. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. Lancet. 2021 Mar 13;397(10278):947–950.
   PubMed Web of Science ®Google Scholar
• Hotez PJ. COVID-19 vaccines: the imperfect instruments of vaccine diplomacy. J Travel Med. 2022 May 24;29(8). DOI:10.1093/jtm/taac063
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Narayan KMV. Restoring vaccine diplomacy. JAMA. 2021 Jun 15;325(23):2337–2338.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME, Strych U. New vaccines for the world’s poorest people. Annu Rev Med. 2016;67(1):405–417.
   PubMedGoogle Scholar
• Bottazzi ME, Hotez PJ. Running the Gauntlet”: formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action. Hum Vaccin Immunother. 2019;15(10):2235–2242.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME. Whole inactivated virus and protein-based COVID-19 vaccines. Annu Rev Med. 2022 Jan 27;73(1):55–64.
   PubMedGoogle Scholar
• Hotez P, Bottazzi ME A COVID vaccine for all: Scientific American; 2021 [Dec 5, 2022]. Available from: https://www.scientificamerican.com/article/a-covid-vaccine-for-all/
   Google Scholar
• Government of India Ministry of Health and Welfare. Vaccination state data 2022 [Dec 5, 2022]. Available from: https://www.mohfw.gov.in/pdf/CummulativeCovidVaccinationReport05Dec2022.pdf
   Google Scholar
• IndoVac can be used by the elderly for the second booster of the Covid-19 vaccine [Internet]. Biofarma; 2022; Nov 23, 2022 [cited Dec 7, 2022]. Available from: https://www.biofarma.co.id/en/latest-news/detail/indovac-can-be-used-by-the-elderly-for-the-second-booster-of-the-covid19-vaccine-
   Google Scholar
• Jiang S, Bottazzi ME, Du L, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec;11(12):1405–1413.
   PubMed Web of Science ®Google Scholar
• Chen WH, Du L, Chag SM, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10(3):648–658. DOI:10.4161/hv.27464
   PubMed Web of Science ®Google Scholar
• Chen WH, Chag SM, Poongavanam MV, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate. J Pharm Sci. 2017 Aug;106(8):1961–1970.
   PubMed Web of Science ®Google Scholar
• Chen WH, Tao X, Agrawal AS, et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 Nov 3;38(47):7533–7541. DOI:10.1016/j.vaccine.2020.09.061
   PubMed Web of Science ®Google Scholar
• Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020 Jun 2;16(6):1239–1242.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME, Corry DB. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. 2020 May;22(4–5):165–167.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 Jun;20(6):347–348.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Corry DB, Strych U, et al. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 Jul;20(7):399–400.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Corey L, Fernandes P, et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020 Nov 4;12(568). DOI:10.1126/scitranslmed.abe0948
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhang X, Yang Y, et al. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 Dec;4(12):1134–1139.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME, Gromowski G. Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020 Jul;14(7):e0008548.
   PubMed Web of Science ®Google Scholar
• Chen WH, Wei J, Kundu RT, et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129893.
   PubMed Web of Science ®Google Scholar
• Pollet J, Chen WH, Versteeg L, et al. SARS‑CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 Aug 3;17(8):2356–2366. DOI:10.1080/21645515.2021.1901545
   PubMed Web of Science ®Google Scholar
• Pollet J, Strych U, Chen WH, et al. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 Jun 9;40(26):3655–3663. DOI:10.1016/j.vaccine.2022.05.007
   PubMed Web of Science ®Google Scholar
• Nanishi E, Borriello F, O’Meara TR, et al. An aluminum hydroxide: CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26;14(629):eabj5305. DOI:10.1126/scitranslmed.abj5305
   PubMed Web of Science ®Google Scholar
• Lee J, Liu Z, Chen WH, et al. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May;105(10):4153–4165.
   PubMed Web of Science ®Google Scholar
• Pino M, Abid T, Pereira Ribeiro S, et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 Jul 15;6(61). DOI:10.1126/sciimmunol.abh3634
   PubMed Web of Science ®Google Scholar
• Thuluva S, Paradkar V, Gunneri SR, et al. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine. 2022 Sep;83:104217.
   PubMed Web of Science ®Google Scholar
• Thuluva S, Paradkar V, Gunneri S, et al. Immunogenic superiority and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdox1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial. Hum Vaccin Immunother. 2023 Apr;27:2203632. DOI:10.1080/21645515.2023.2203632
   Google Scholar
• Thuluva S, Paradkar V, Gunneri S, et al. Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: a prospective, randomised, double-blind, placebo controlled, phase-2/3 study. Vaccine. 2022 Nov 22;40(49):7130–7140. DOI:10.1016/j.vaccine.2022.10.045
   PubMed Web of Science ®Google Scholar
• Chen WH, Pollet J, Strych U, et al. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 Feb;190:106003.
   PubMed Web of Science ®Google Scholar
• Marc LaForce F, Ravenscroft N, Djingarey M, et al. Epidemic meningitis due to Group a Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009 Jun 24;27 Suppl 2:B13–9. DOI:10.1016/j.vaccine.2009.04.062
   PubMed Web of Science ®Google Scholar
• Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021 Mar;170:71–82.
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022 Aug;608(7923):603–608.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. Coronaviruses closely related to the pandemic virus discovered in Japan and Cambodia. Nature. 2020 Dec;588(7836):15–16.
   PubMed Web of Science ®Google Scholar
• Pitcovski J, Gruzdev N, Abzach A, et al. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine. Vaccine. 2022 Feb 16;40(8):1098–1107. DOI:10.1016/j.vaccine.2022.01.025
   PubMed Web of Science ®Google Scholar